FDA Grants AP Status for Sufentanil Citrate ANDA074534 by Hospira
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Sufentanil Citrate submitted by Hospira.
Asset
Hospira
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Sufentanil Citrate by Hospira is significant as it positions the company to compete more effectively in the anesthesia market. Strategic teams should evaluate the implications for market dynamics and pricing strategies as this product approaches market entry.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for the final approval and market entry timeline for Sufentanil Citrate.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.